Edwards Lifesciences announced on November 25, 2024, compelling one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. An analysis of over 9,000 propensity-matched patients from the STS/ACC TVT Registry demonstrated superior outcomes compared to earlier generation SAPIEN 3 and SAPIEN 3 Ultra valves.
Patients treated with the SAPIEN 3 Ultra RESILIA valve experienced extremely low mortality rates and low rates of reintervention. The data also showed larger effective orifice areas, lower echo-derived gradients across all valve sizes, and no paravalvular leak in 84.4% of cases.
These strong real-world data, combined with over 10 years of clinical experience with RESILIA tissue, reinforce the SAPIEN platform's ability to deliver excellent patient outcomes with rapid recovery and improved quality of life. This further solidifies Edwards' leadership in transcatheter aortic valve replacement (TAVR).
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.